Home
Search:
1146 feeds
357 categories
0 articles (<24 hours)
35 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

Science


RSS FeedsXencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
(World News Science)

 
 

12 july 2018 23:31:28

 
Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
(World News Science)
 


MONROVIA, Calif., July 12, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been dosed in XmAb20717-01 (DUET-2), a Phase 1, first-in-human, clinical trial of XmAb®20717, a bispecific antibody that simultaneously targets PD-1 and CTLA-4 immune checkpoints for the treatment of multiple advanced solid tumors. `Built on the scaffold of Xencor`s XmAb® bispecific Fc domain, XmAb20717 is the most advanced candidate in our suite of tumor microenvironment activators,` said Paul Foster,...


 
17 viewsCategory: Science
 
ShiftPixy Provides Update on Release of Fiscal Third Quarter 2018 Results
(World News Science)
Google`s `Mobile Speed Score` Update
(World News Science)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten